. 2021 Dec;16(12):1790–1796. doi: 10.2215/CJN.01070121

Table 2.

Association of high-risk APOL1 genotype with AKI

Outcome	Overall Study Cohort, n=126	No. of APOL1 High-Risk Alleles		Adjusted Odds Ratio^a (95% Confidence Interval)	P Value
Outcome	Overall Study Cohort, n=126	0 or 1, n=110; 87%	2, n=16; 13%	Adjusted Odds Ratio^a (95% Confidence Interval)	P Value
Primary composite outcome, n (%)
AKI	50 (40)	39 (35)	11 (69)	4.41 (1.11 to 17.52)	0.04
Secondary outcomes, n (%)
Persistent AKI	29 (23)	21 (19)	8 (50)	3.53 (1.08 to 11.57)	0.04
AKI requiring KRT	12 (10)	8 (7)	4 (25)	4.99 (1.02 to 24.40)	0.05

The primary exposure was two APOL1 high-risk alleles. Unadjusted odds ratio estimates are AKI: odds ratio, 4.01; 95% confidence interval, 1.30 to 12.36; P=0.02; persistent AKI: odds ratio, 4.24; 95% confidence interval, 1.43 to 12.60; P=0.01; and AKI KRT: odds ratio, 4.25; 95% confidence interval, 1.11 to 16.25; P=0.03.

^{^a}

Adjusted for age, sex, body mass index, hypertension, eGFR, and use of angiotensin receptor blocker/angiotensin-converting enzyme inhibitor.